Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow BOLD by emailGet an email when BOLD pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about BOLD, unsubscribe in one click. Privacy
📣 What BOLD Says Is Next
second half of 2029 · “The combined company’s cash and cash equivalents balance at closing, including the funds from the private placement, is expected to fund Serapha’s operations into the second half of 2029 and provide runway through Phase 2 completion and Phase 3 initiation for SERP-01.”
Company press release, Jun 23, 2026 · SEC filing
second half of 2028 · “The Company expects its cash to fund operations into the second half of 2028, through the anticipated initial clinical proof-of-concept readout from KOMODO-1.”
Company press release, Mar 9, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full BOLD picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for BOLD and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.